Paper8345587
Hereditary prostate cancer: epidemiologic and clinical features.
Carter BS and 6 others. J Urol, 1993. Cited by 425 papers, by iCite.
Cite this record
ConductScience Library. Hereditary prostate cancer: epidemiologic and clinical features. Papers, record 8345587. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8345587
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prostatic Neoplasms | Major topic |
| Humans | |
| Male | |
| Models, Biological | |
| Pedigree | |
| Risk Factors |
Source PubMed
Cited by124
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 425 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40891997 | Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer. | BJU Int | 2025 | https://conductscience.org/library/papers/40891997 | PubMed |
| 39874495 | Coding Variants of the Genitourinary Development Gene WNT9B Carry High Risk for Prostate Cancer. | JCO Precis Oncol | 2025 | https://conductscience.org/library/papers/39874495 | PubMed |
| 39807695 | Exploring experimental models of prostate cancer in chemoprevention: Oxidative stress as a key pathway to translational research. | Pathol Int | 2025 | https://conductscience.org/library/papers/39807695 | PubMed |
| 38736618 | Cribiform and intraductal carcinoma in hereditary prostate cancer: clinical and pathological analysis of 20 cases. | Am J Clin Exp Urol | 2024 | https://conductscience.org/library/papers/38736618 | PubMed |
| 38534919 | Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer. | Curr Oncol | 2024 | https://conductscience.org/library/papers/38534919 | PubMed |
| 37528288 | Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer. | World J Urol | 2023 | https://conductscience.org/library/papers/37528288 | PubMed |
| 37046747 | High-Risk Pedigree Study Identifies LRBA (rs62346982) as a Likely Predisposition Variant for Prostate Cancer. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37046747 | PubMed |
| 36434163 | Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine. | Prostate Cancer Prostatic Dis | 2023 | https://conductscience.org/library/papers/36434163 | PubMed |
| 36060024 | Variants in HOXB13, G132E and F127C, Are Associated With Prostate Cancer Risk in Japanese Men. | Cancer Diagn Progn | 2022 | https://conductscience.org/library/papers/36060024 | PubMed |
| 35449224 | Germline testing and genetic counselling in prostate cancer. | Nat Rev Urol | 2022 | https://conductscience.org/library/papers/35449224 | PubMed |
| 35104804 | Health inequity drives disease biology to create disparities in prostate cancer outcomes. | J Clin Invest | 2022 | https://conductscience.org/library/papers/35104804 | PubMed |
| 34211358 | Innovations in 3-Dimensional Tissue Models of Human Brain Physiology and Diseases. | Adv Funct Mater | 2020 | https://conductscience.org/library/papers/34211358 | PubMed |
| 34164591 | Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. | JCO Precis Oncol | 2017 | https://conductscience.org/library/papers/34164591 | PubMed |
| 34118026 | Recent Insights on Genetic Testing in Primary Prostate Cancer. | Mol Diagn Ther | 2021 | https://conductscience.org/library/papers/34118026 | PubMed |
| 34059701 | Prostate cancer risk variants of the HOXB genetic locus. | Sci Rep | 2021 | https://conductscience.org/library/papers/34059701 | PubMed |
| 33973043 | Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance. | World J Urol | 2021 | https://conductscience.org/library/papers/33973043 | PubMed |
| 33780364 | Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer. | Cancer Biomark | 2021 | https://conductscience.org/library/papers/33780364 | PubMed |
| 33721089 | [Familial prostate cancer and genetic predisposition]. | Urologe A | 2021 | https://conductscience.org/library/papers/33721089 | PubMed |
| 33486571 | Genetic predisposition to prostate cancer: an update. | Fam Cancer | 2022 | https://conductscience.org/library/papers/33486571 | PubMed |
| 33351846 | Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort. | PLoS One | 2020 | https://conductscience.org/library/papers/33351846 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8345587
GET https://conductscience.org/api/papers/v1/8345587/cited_by?page=2